[COVID-19: Coagulopathy and thrombosis]. / COVID-19 : coagulopathie et thrombose.
Rev Med Interne
; 42(2): 93-100, 2021 Feb.
Article
in French
| MEDLINE | ID: covidwho-1118648
ABSTRACT
The SARS-CoV-2 virus caused a global pandemic within weeks. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe COVID-19 develop sometimes unrecognized, venous thromboembolic complications. A better understanding of COVID-19 pathophysiology, in particular hemostatic disorders, will help to choose appropriate treatment strategies. A rigorous thrombotic risk assessment and the implementation of a suitable anticoagulation strategy are required. We review here the characteristics of COVID-19 coagulation laboratory findings in affected patients, the incidence of thromboembolic events and their specificities, and potential therapeutic interventions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pulmonary Embolism
/
Blood Coagulation Disorders
/
Venous Thromboembolism
/
SARS-CoV-2
/
COVID-19
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
French
Journal:
Rev Med Interne
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS